Table 1.
Baseline characteristics of patients included in the study (n = 85)
| Age, yrs | 45 (38–54) | ||
| Female sex | 73 (86) | ||
| BMI, kg/m2 | 42 (40–45) | ||
| Smoking | 15 (18) | ||
| Number of regular prescription drugsa | 4 (2–6) | ||
| Psychotropic/antiepileptic substance | SSRIs | Citalopram/escitalopram | 18 (21) |
| Fluoxetine | 15 (18) | ||
| Paroxetine | 1 (1.2) | ||
| Sertraline | 13 (15) | ||
| SNRIs | Duloxetine | 9 (11) | |
| Venlafaxine | 16 (19) | ||
| TCAs | Amitriptyline | 3 (3.5) | |
| Clomipramine | 2 (2.4) | ||
| Other antidepressants | Bupropion | 2 (2.4) | |
| Mianserine | 3 (3.5) | ||
| Mirtazapine | 6 (7.1) | ||
| Antipsychotics | Olanzapine | 1 (1.2) | |
| Quetiapine | 2 (2.4) | ||
| Antiepileptics | Gabapentin | 2 (2.4) | |
| Lamotrigine | 4 (4.7) | ||
| Pregabalin | 7 (8.2) | ||
| Topiramate | 4 (4.7) | ||
| Valproic acid | 2 (2.4) | ||
| Reason for treatmentb | Depression | 50 (59) | |
| Anxiety | 22 (26) | ||
| Pain | 9 (11) | ||
| Fibromyalgia | 5 (5.9) | ||
| Bipolar disease | 5 (5.9) | ||
| Burnout | 4 (4.7) | ||
| Sleep problems | 2 (2.4) | ||
| Epilepsy | 1 (1.2) | ||
| Other | 10 (12) | ||
| Surgery | Gastric bypass | 67 (79) | |
| Sleeve | 18 (21) | ||
Values are presented as medians (interquartile range (IQR)) or n (percentage)
BMI body mass index, SNRI serotonin–norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TCA tricyclic antidepressant
aReflecting burden of disease (see Brilleman and Salisbury [31])
bSome patients had more than one reason for treatment with a psychotropic/antiepileptic drug